Trials / Completed
CompletedNCT03761082
Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 258 (actual)
- Sponsor
- IlDong Pharmaceutical Co Ltd · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Post-marketing surveillance of Pirfenidone
Detailed description
Pirfenidone (Pirespa®) is an anti fibrotic drug, which was approved in 2012 in the Republic of Korea for the treatment of patients with idiopathic pulmonary fibrosis (IPF). A post-marketing survey was conducted following the approval to obtain data on the safety and efficacy of pirfenidone for IPF treatment in real-world practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | NA(observation study) | NA(observation study) |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2018-12-03
- Last updated
- 2019-07-10
Source: ClinicalTrials.gov record NCT03761082. Inclusion in this directory is not an endorsement.